Rosuvastatin Calcium
Based on 24 publication(s) in Google Scholar
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 147098-20-2
- Formula: C22H27Ca0.5FN3O6S
- Molecular Weight:500.57
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Antibacterial Compound Library
HY-L049
-
Ferroptosis Compound Library
HY-L051
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Lipid Metabolism Compound Library
HY-L091
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Potassium Channel Compound Library
HY-L119
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Ion Channel Compound Library
HY-L166
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Rosuvastatin Calcium
More- Cell Metab. 2025 Sep 2;37(9):1907-1925.e14. [Abstract]
- Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
- MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]
- Biosens Bioelectron. 2025 Nov 15:288:117807. [Abstract]
- Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428. [Abstract]
- Phytomedicine. 2025 Jun 19:145:157014. [Abstract]
- Phytomedicine. 2024 Jul:129:155621. [Abstract]
- Biomed Pharmacother. 2025 Oct 21:192:118665. [Abstract]
- Cell Death Discov. 2024 May 29;10(1):263. [Abstract]
- Front Bioeng Biotechnol. 2022 Mar 17;10:826093. [Abstract]
- Eur J Pharmacol. 2023 Sep 15:955:175911. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Pharm Res. 2025 Oct 27. [Abstract]
- Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
- Front Cell Dev Biol. 2021 May 6;9:651579. [Abstract]
- J Inflamm Res. 2021 Apr 16:14:1537-1549. [Abstract]
- Cell Signal. 2025 Jul:131:111753. [Abstract]
- Front Oncol. 2021 May 10:11:595285. [Abstract]
- PLoS One. 2026 Feb 20;21(2):e0339967. [Abstract]
- Exp Ther Med. 2021 Oct;22(4):1189. [Abstract]
- Vasc Endovasc Rev. 2025 Nov 7.
- J Nephropharmacol. 2025 Sep 20:e12798
- World J Methodol. 2025 Jun 20;15(2):99580. [Abstract]
- bioRxiv. 2024 November 08.
Customer Validation & Images
-
WB
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins Calcium (VLDL) in diabetes mellitus rats induced by Streptozocin[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 147098-20-2
-
Appearance Solid
-
Molecular Weight 500.57
-
Formula C22H27Ca0.5FN3O6S
-
Color White to off-white
-
SMILES
O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2.[0.5Ca2+]
-
Synonyms
Rosuvastatin hemicalcium; ZD 4522 Calcium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. [Abstract]2025 Sep 2;37(9):1907-1925.e14. PMID: 40803319 -
Adv Sci (Weinh)
Short-Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation. [Abstract]2024 Jul 5:e2403451. PMID: 38970167
Rosuvastatin Calcium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
Western blotting of PAQR9 in mouse primary hepatocytes under the treatment of DMSO, simvastatin (Sim), atorvastatin (Ator), and rosuvastatin (Rosu) (10 μM; 24–48 h) was performed.
-
MedComm (2020)
Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [Abstract]2024 Aug 31;5(9):e681. PMID: 39220103
Rosuvastatin Calcium purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]
Chemerin levels in the medium of HepG2 cells cultured for 48 h, in the absence (control) or presence of atorvastatin, evolocumab, or Rosuvastatin, were measured.
-
Biosens Bioelectron
Drug functionalized organic electromechanical transistor for rapid and sensitive detection of C-reactive protein. [Abstract]2025 Nov 15:288:117807. PMID: 40712486 -
Acta Pharmacol Sin
2023 Jul;44(7):1416-1428. PMID: 36721007
Rosuvastatin Calcium purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428. [Abstract]
Rosuvastatin calcium (10 mg/kg body weight every second day, n = 5) was administered. The body weights of control and bavachin-treated mice were measured weekly from weeks 1 to 20.
-
Phytomedicine
Theaflavin-3,3'-digallate stabilizes vulnerable plaques by reprogramming metabolic homeostasis in neovascularization via HK2/TIGAR. [Abstract]2025 Jun 19:145:157014. PMID: 40570559 -
Phytomedicine
Gut microbiome and metabolomic profiles reveal the antiatherosclerotic effect of indole-3-carbinol in high-choline-fed ApoE-/- mice. [Abstract]2024 Jul:129:155621. PMID: 38678950 -
Biomed Pharmacother
Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment. [Abstract]2025 Oct 21:192:118665. PMID: 41124864 -
Cell Death Discov
Upregulation of rate-limiting enzymes in cholesterol metabolism by PKCδ mediates endothelial apoptosis in diabetic wound healing. [Abstract]2024 May 29;10(1):263. PMID: 38811564
Rosuvastatin Calcium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 May 29;10(1):263. [Abstract]
Rosuvastatin calcium (5 mg/kg i.p.) was administered. Images of the wound area in the rosuvastatin calcium-treated group and the control group were captured.
Rosuvastatin Calcium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 May 29;10(1):263. [Abstract]
Rosuvastatin calcium (5 mg/kg i.p.) was administered. The free cholesterol level of skin tissue after rosuvastatin calcium treatment for 12 days was measured. Each experiment was replicated at least thrice and representative images were shown.
-
Front Bioeng Biotechnol
Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]2022 Mar 17;10:826093. PMID: 35372314 -
Eur J Pharmacol
Combining idebenone and rosuvastatin prevents atherosclerosis by suppressing oxidative stress and NLRP3 inflammasome activation. [Abstract]2023 Sep 15:955:175911. PMID: 37451421 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Pharm Res
Profiling Interactions Between Bicyclol and SLC/ABC Transporters: Advancing Clinical Safety and Efficacy in Combination Therapy. [Abstract]2025 Oct 27. PMID: 41145746 -
Front Cell Dev Biol
Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]2022 Mar 3;10:806081. PMID: 35309902 -
Front Cell Dev Biol
2021 May 6;9:651579. PMID: 34026753 -
J Inflamm Res
Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na,K-ATPase via the PI3K/AKT/Nedd4-2 Pathway. [Abstract]2021 Apr 16:14:1537-1549. PMID: 33889010 -
Cell Signal
Rosuvastatin inhibits carcinogenesis through Ca2+ triggered endoplasmic reticulum stress pathway in pancreatic cancer. [Abstract]2025 Jul:131:111753. PMID: 40107481 -
Front Oncol
Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. [Abstract]2021 May 10:11:595285. PMID: 34041015 -
PLoS One
Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway. [Abstract]2026 Feb 20;21(2):e0339967. PMID: 41719299 -
Exp Ther Med
Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. [Abstract]2021 Oct;22(4):1189. PMID: 34475979 -
-
-
World J Methodol
Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy. [Abstract]2025 Jun 20;15(2):99580. PMID: 40548212 -
Solvent & Solubility
DMSO : 25 mg/mL (49.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (2.00 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Handling Instructions (2659 KB)
References
[1]. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44. [Content Brief]
[2]. Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7. [Content Brief]
[3]. Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78. [Content Brief]
[4]. Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.9977 mL | 9.9886 mL | 19.9772 mL | 49.9431 mL |
| DMSO | 5 mM | 0.3995 mL | 1.9977 mL | 3.9954 mL | 9.9886 mL |
| 10 mM | 0.1998 mL | 0.9989 mL | 1.9977 mL | 4.9943 mL | |
| 15 mM | 0.1332 mL | 0.6659 mL | 1.3318 mL | 3.3295 mL | |
| 20 mM | 0.0999 mL | 0.4994 mL | 0.9989 mL | 2.4972 mL | |
| 25 mM | 0.0799 mL | 0.3995 mL | 0.7991 mL | 1.9977 mL | |
| 30 mM | 0.0666 mL | 0.3330 mL | 0.6659 mL | 1.6648 mL | |
| 40 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2486 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz